Millendo Therapeutics, Inc.
MLND · NASDAQ
12/31/2024 | 12/31/2020 | 12/31/2019 | 12/31/2018 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.00 | 0.00 | 0.00 | 0.00 |
| FCF Yield | -1.47% | -1,131.93% | -675.75% | -2,888.39% |
| EV / EBITDA | 0.00 | 0.93 | 1.16 | 2.66 |
| Quality | ||||
| ROIC | 0.00% | -98.83% | -70.49% | -35.87% |
| Gross Margin | 0.00% | 0.00% | 0.00% | 0.00% |
| Cash Conversion Ratio | – | 0.84 | 0.92 | 0.87 |
| Growth | ||||
| Revenue 3-Year CAGR | – | – | -100.00% | -100.00% |
| Free Cash Flow Growth | 0.00% | 26.81% | -75.73% | 48.19% |
| Safety | ||||
| Net Debt / EBITDA | 0.00 | 1.01 | 1.30 | 2.69 |
| Interest Coverage | 0.00 | 0.00 | 43.74 | -200.55 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | 0.00 | 0.00 | 0.00 |